Expert Opin Pharmacother 2008 Feb;9(3):459-65
Montreal Neurological Institute, Canada.
Background: Although the role of clozapine is well established for treatment-resistant schizophrenia, it is rarely used in pediatric populations, mainly due to its potentially serious adverse effects.
Objective: To summarize practical aspects of use of clozapine in treating children with schizophrenia and management of associated adverse effects.
Methods: Available studies in the literature using clozapine in the pediatric population are summarized and the NIMH experience in treating refractory childhood-onset schizophrenia cases with clozapine is discussed.
Conclusion: Despite a higher incidence of adverse effects in children, clozapine appears to be a uniquely beneficial second-line agent for treating children with refractory schizophrenia.